Palisade Bio Inc

0.00 (0.00%)
Earnings Announcements

Palisade Bio Reports Qtrly Loss Per Share $0.26

Published: 05/13/2022 13:11 GMT
Palisade Bio Inc (PALI) - Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update.
Palisade Bio Inc - Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function on Track to Commence Q2 2022.
Palisade Bio Inc - Ongoing Phase 2 Study of Lb1148 for Prevention of Post-surgical Abdominal Adhesions.
Palisade Bio Inc - As of March 31, 2022, Company Had Cash and Cash Equivalents of $6.6 Million.
Palisade Bio Inc - Qtrly Loss per Share $0.26.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.